May 14, 2026 Tirofiban After Tenecteplase in Stroke Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke. Conexiant
May 14, 2026 Tenecteplase Prior to EVT Did Not Improve Stroke Outcomes Phase 3 trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients. Conexiant
May 13, 2026 AI Discharge Summaries Show Low Harm Risk Most reviewed summaries were rated as posing no harm risk, although omissions remained common. Conexiant
May 13, 2026 PCOS Renamed PMOS After Global Consensus International initiative reframes a common endocrine disorder around its metabolic and ovarian features rather than ovarian cysts Conexiant
May 12, 2026 Digitalis Reduces HF Events but Not Mortality Meta-analysis of randomized trials found fewer worsening heart failure events among patients with reduced or mildly reduced ejection fraction Conexiant
May 06, 2026 Rapid AST Speeds Care, Not Outcomes Faster antibiotic optimization may still support use of rapid testing, particularly when paired with stewardship. Conexiant
May 06, 2026 Dalbavancin Exposure Linked to Higher Success in Bacteremia Higher day 22 concentrations were associated with improved outcomes, though findings remain exploratory Conexiant
May 01, 2026 Philadelphia Institutions Launch Glaucoma Research Retreat Researchers from 5 institutions met to discuss neuroprotection, diagnostics, gene therapy, and regional collaboration. Glaucoma Physician
April 29, 2026 FDA Monthly Preview: Key May Decisions to Watch Several FDA decisions across multiple specialties are expected this month. Conexiant
April 28, 2026 This Week’s Biopharma News: Wave of Antibody Approvals FDA expands Tzield, EU clears Dupixent, and Health Canada approves denosumab antibody biosimilars The Medicine Maker